Is it ‘Take Profit’ Time for LivaNova (LIVN)?

Diamond Hill Capital, an investment management firm, published its “Diamond Hill Small Cap Fund” third-quarter 2021 investor letter – a copy of which can be downloaded here. The portfolio outpaced the Russell 2000® Index in the quarter, delivering nearly a 2% positive return against the index’s negative return and adding to year-to-date outperformance.  You can take a look at the fund’s top 5 holdings to have an idea about their best picks for 2021.

Diamond Hill Small Cap Fund, in its Q3 2021 investor letter, mentioned LivaNova PLC (NASDAQ: LIVN) and discussed its stance on the firm. LivaNova PLC is a United Kingdom-based medical device company with a $4.5 billion market capitalization. LIVN delivered a 30.00% return since the beginning of the year, while its 12-month returns are up by 73.25%. The stock closed at $86.07 per share on November 12, 2021.

Here is what Diamond Hill Small Cap Fund has to say about LivaNova PLC  in its Q3 2021 investor letter:

“Our health care holdings were negative in aggregate, but outpaced index peers, which boosted relative performance along with our below-benchmark positioningOn an individual holdings’ basis, we exited global medical technology company LivaNova as shares approached our estimate of intrinsic value.”

national-cancer-institute-GcrSgHDrniY-unsplash

Based on our calculations, LivaNova PLC (NASDAQ: LIVN) was not able to clinch a spot in our list of the 30 Most Popular Stocks Among Hedge Funds. LIVN was in 36 hedge fund portfolios at the end of the first half of 2021, compared to 28 funds in the previous quarter. LivaNova PLC (NASDAQ: LIVN) delivered a 4.93% return in the past 3 months.

Disclosure: None. This article is originally published at Insider Monkey.